BioStock: Broad political support benefits DanCann Pharma
The temporary Danish Pilot Programme that allows the prescription of medical cannabis to patients has been a great success. Last week, Danish politicians agreed to extend the programme for an additional four years, while also permanently allowing companies to manufacture cannabis for medical use. The unanimous decision will benefit companies like DanCann Pharma, not least in terms of making investments in the cannabinoid sphere safer, but also by making more patients and doctors aware of the extended treatment options.Read the full article about DanCann Pharma at biostock.se: https://www.